A biphasic opioid function modulator: agmatine.
Recently it has been revealed that some agents that are not able to interact with opioid receptors play an important role in regulating the pharmacological actions of opioids. Especially, some of them show biphasic modulation on opioid functions, which enhance opioid analgesia, but inhibit tolerance to and substance dependence on opioids. We would like to call these agents which do not interact with opioid receptors, but do have biphasic modulation on opioid functions as biphasic opioid function modulator (BOFM). Mainly based on our results, agmatine is a typical BOFM. Agmatine itself was a weak analgesic which enhanced analgesic action of morphine and inhibited tolerance to and dependence on opioid. The main mechanisms of agmatine were related to inhibition of the adaptation of opioid receptor signal transduction induced by chronic treatment of opioid.
Su
Rui-Bin
RB
Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
Li
Jin
J
Qin
Bo-Yi
BY
D000376:Agmatine / Q000494:pharmacology*; D000698:Analgesia; D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D004347:Drug Interactions; D004361:Drug Tolerance; D009020:Morphine / Q000494:pharmacology*; D009021:Morphine Dependence / Q000517:prevention & control; D018377:Neurotransmitter Agents / Q000494:pharmacology; D011957:Receptors, Opioid / Q000187:drug effects / Q000378:metabolism; D015398:Signal Transduction
D000701:Analgesics, Opioid; D018377:Neurotransmitter Agents; D011957:Receptors, Opioid; D000376:Agmatine; D009020:Morphine